Yahoo Finance Glaukos Corp (GKOS) Q1 2024 Earnings: Misses Analyst EPS Forecast, Surpasses Revenue Expectations
Revenue: Reported $85.6 million, a 16% increase year-over-year, surpassing the estimate of $79.60 million.
Net Loss: Reported $40.8 million, widened from $34.6 million year-over-year, exceeding surpassing the estimated loss of $28.25 million.
Earnings Per Share (EPS): Reported a loss of $0.82 per diluted share, deeper than surpassing the estimated loss of $0.57 per share.
Gross Margin: Maintained at approximately 76%, consistent with the previous year.
Research and Development Expenses: Decreased by 13% to $30.7 million, down from $35.2 million in the same period last year.
2024 Revenue Guidance: Projected to be between $357 million and $365 million, aligning closely with surpassing the annual estimated revenue of $356.67 million.
Cash Position: Ended the quarter with approximately $279 million in cash, cash equivalents, short-term investments, and restricted cash.
On May 1, 2024, Glaukos Corp (NYSE:GKOS), a leader in ophthalmic medical technology, released its first quarter financial results through its 8-K filing. The company reported a net loss of $40.8 million, or ($0.82) per diluted share, which did not meet analyst expectations of a $0.57 loss per share. However, it exceeded revenue estimates, posting $85.6 million against the forecasted $79.60 million.
Glaukos is renowned for its innovative solutions in the treatment of glaucoma, corneal disorders, and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery (MIGS) with the launch of its first MIGS device in 2012, continually expanding its portfolio with new technologies.
Financial Highlights and Strategic Execution
The first quarter of 2024 saw a 16% increase in net sales year-over-year, reaching $85.6 million. This growth is attributed to the effective global execution of the company's strategic plans, particularly in advancing its pipeline of novel, dropless platform technologies. According to Thomas Burns, Glaukos chairman and CEO, these technologies are set to significantly improve patient outcomes in chronic eye diseases.
Despite the revenue growth, Glaukos experienced a widening in its operating loss, which grew from $33.0 million in Q1 2023 to $39.1 million in Q1 2024. This increase in loss was partly due to a $11.7 million charge related to acquired in-process R&D. The non-GAAP loss from operations was $32.8 million, compared to $26.8 million in the previous year.
Operational and Financial Metrics
The company maintained a gross margin of 76% in Q1 2024, consistent with the previous year. Selling, general and administrative (SG&A) expenses rose by 16% to $62.0 million, reflecting increased operational activities. Research and development (R&D) expenses, however, saw a decrease of 13% to $30.7 million.
Glaukos ended the quarter with a strong balance sheet, holding approximately $279 million in cash, cash equivalents, and short-term investments. Looking forward, Glaukos has set its 2024 revenue guidance to range between $357 million and $365 million.
Industry Impact and Investor Outlook
The financial achievements of Glaukos underscore its commitment to innovation and leadership in the ophthalmic sector. By consistently advancing its product pipeline and maintaining robust sales growth, Glaukos not only enhances its market position but also offers promising prospects for investors interested in medical technology and healthcare advancements.
Investors and stakeholders are encouraged to review the detailed financial tables and GAAP to Non-GAAP reconciliations provided in the company's filings. These documents offer a deeper insight into Glaukos' operational and financial metrics, crucial for making informed investment decisions.
For further details, Glaukos will host a conference call and webcast to discuss the results and provide additional insights into the companys financial outlook. This interactive session will primarily focus on addressing investor queries, reflecting Glaukos' commitment to transparency and stakeholder engagement.
The company's continuous innovation, coupled with strategic market expansions, positions it well for future growth, despite the challenges posed by competitive pressures and market dynamics in the medical technology landscape.
Explore the complete 8-K earnings release (here) from Glaukos Corp for further details.
This article first appeared on GuruFocus.
